Global obsessive-compulsive disorder drug market to grow with steady CAGR in the forecast period of 2019-2026 with Top  Players like Abbott, Pfizer Inc., Merck & Co., Inc., Sanofi, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca, Meiji Holdings Co., Ltd

Obsessive-compulsive disorder is mental disorders that is characterized by repeated pattern of unreasonable thoughts and fears and make you to do unwanted activities. It affects patients of all age. Patient may experience intrusive thoughts, under stress all the time, and unnecessary fears etc. According to the article published in The Oaks at La Paloma Treatment Center, 2018, it was estimated that over 2.2 million patients diagnosed with obsessive-compulsive disorder in the United States in which the ration of man and women are equally prevalent. Increasing cases of OCD worldwide, changes in life style and environmental stress among people are the drivers to the market growth.

 Global obsessive-compulsive disorder drug market to grow with substantial CAGR in the forecast period of 2019-2026 with Top  Players like Abbott, Pfizer Inc., Merck & Co., Inc., Sanofi, Novartis AG, AbbVie Inc, Eli Lilly and Company, AstraZeneca, Meiji Holdings Co., Ltd, Brainsway, Sellas, Mylan N.V., Addex therapeutics, F. Hoffmann-La Roche Ltd., Omeros Corporation,  C4x discovery holdings plc. Zydus Cadila and among others.

Key Developments in the Market:

  • In August 2018, Brainsway received marketing approval from the FDA for Deep Transcranial Magnetic Stimulation System, a device that stimulates the nerve cells in the brain for treatment of obsessive compulsive disorder (OCD)
  • In December 2017, Zydus Cadila received FDA approval for clomipramine hydrochloride for the treatment of obsessive compulsive disorder (OCD)

Competitive Analysis: Global obsessive-compulsive disorder drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of obsessive-compulsive disorder drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

 Reasons to Purchase this Report

  • Current and future of global obsessive-compulsive disorder drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Market Drivers

  • Increases of cases of prevalence rate of infectious diseases worldwide
  • Advances in treatment, therapies and novel treatment
  • Robust pipelines for development of newer treatment

Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry of the patented drugs and introduction of generic version of branded drugs is expected to restrain the growth if the market
  • Inadequate awareness about obsessive-compulsive disorder treatment in some developing countries

Table of Contents

Study Coverage

Executive Summary

Market Size-by Manufacturers

Production-by Regions

Consumption-by Regions

Market Size-by Type

Market Size-by Application

Manufacturers Profiles

Production Forecasts

Consumption Forecast

Upstream, Industry Chain and Downstream Customers Analysis

Opportunities & Challenges, Threat and Affecting Factors

Key Findings


Request Complete TOC Of this Report @


By Symptoms Type

  • Contamination Obsessions with Cleaning Compulsions
  • Checking Compulsions
  • Obsessions without Visible Compulsions
  • Symmetry obsessions with ordering compulsions
  • Hoarding
  • Others

By Therapy Type

  • Cognitive behavioral therapy
  • Aversion therapy
  • Augmentation therapy
  • Systematic desensitization
  • Others

By Mechanism Class Type

  • Anti-depressants
  • Anti-anxiety
  • Anti-psychotics
  • Benzodiazepines

By Mechanism of action type

  • Serotonin-norepinephrine reuptake inhibitors (SNRIs)
    • Venlafaxine
    • Duloxetine
  • Serotonin reuptake inhibitors (SRIs)
    • Clomipramine
  • Selective serotonin reuptake inhibitors (SSRIs)
    • Sertraline
    • Fluoxetine
    • Fluvoxamine
    • Paroxetine

By Brand Type

  • Anafranil
  • Prozac
  • Luvox
  • Paxil
  • Zoloft
  • Others

By Route of administration

  • Oral
  • Injectable

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • S.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Grab Your Report at an Impressive Discount! Please click Here@



About Data Bridge Market Research 12402 Articles
Hi, I am Ravi Kumar, a Blogger, Freelancer, SEO Consultant, an Internet Marketer, I am a research analyst who loves to evaluate data relating to Manufacturing industry, Management of companies and enterprises, Finance and insurance, Wholesale trade, Management, scientific, and technical consulting services

Leave a Reply

Your email address will not be published.